Gilead Sciences (GILD) Gross Margin (2009 - 2026)
Gilead Sciences' (GILD) quarterly Gross Margin came in at 79.24% in Q1 2026, up 234.0% YoY from 23.72% in Q1 2025, and little changed on a QoQ basis from 79.51% in Q4 2025.
Gilead Sciences (GILD) Gross Margin (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Gross Margin data on file, last reported at 79.24% in Q1 2026.
- Quarterly Gross Margin rose 234.0% year-over-year to 79.24% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 79.35% (up 107.0% YoY) and the FY2025 annual result came in at 78.83%, up 57.0% from the prior year.
- Gross Margin held at 79.24% in Q1 2026, from 79.51% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 81.11% in Q4 2022 to a low of 70.62% in Q4 2023.
- A 5-year average of 78.13% and a median of 78.39% in 2022 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2022 — Gross Margin jumped 1737 bps — and 2023, when it plunged 1049 bps.
- Tracing GILD's Gross Margin over 5 years: stood at 81.11% in 2022, then retreated by 13 bps to 70.62% in 2023, then increased by 12 bps to 79.11% in 2024, then grew by 1 bps to 79.51% in 2025, then decreased by 0 bps to 79.24% in 2026.
- The last three Gross Margin figures came in at 79.24% (Q1 2026), 79.51% (Q4 2025), and 79.8% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 68.19% |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 74.74% |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 73.54% |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 78.02% |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 83.60% |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 72.04% |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 79.76% |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 72.78% |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 73.05% |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 80.05% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 79.76% |
| Mar 31, 2026 | 79.24% |
| Dec 31, 2025 | 79.51% |
| Sep 30, 2025 | 79.80% |
| Jun 30, 2025 | 78.81% |
| Mar 31, 2025 | 76.90% |
| Dec 31, 2024 | 79.11% |
| Sep 30, 2024 | 79.14% |
| Jun 30, 2024 | 77.80% |
| Mar 31, 2024 | 76.79% |
| Dec 31, 2023 | 70.62% |
| Sep 30, 2023 | 77.80% |
| Jun 30, 2023 | 78.15% |
| Mar 31, 2023 | 77.94% |
| Dec 31, 2022 | 81.11% |
| Sep 30, 2022 | 80.19% |
| Jun 30, 2022 | 76.96% |
| Mar 31, 2022 | 78.39% |
| Dec 31, 2021 | 63.74% |
| Sep 30, 2021 | 83.52% |